Atreca Announces Appointment of Dr. Lindsey Rolfe to its Board of Directors
27 8월 2019 - 5:05AM
Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company
focused on developing novel therapeutics based on a deep
understanding of the human immune response, today announced
the appointment of Lindsey Rolfe, BSc, MB ChB, MRCP, FFPM, to
the company’s Board of Directors. In addition, Lawrence Steinman,
M.D., Stanford University Professor and co-founder of
Atreca, has resigned from the Board, effective as of
August 22, 2019, but will continue to serve as a technical advisor
to the company.
“As we prepare to submit an Investigational New
Drug (IND) application for ATRC-101 later this year and enter the
clinic in early 2020, Lindsey’s deep oncology expertise and her
experience in the development of oncology therapeutics will be
critical as the company continues to evolve,” said John Orwin,
Chief Executive Officer. “At the same time, I would like to
recognize and thank Dr. Steinman for his contributions and support,
which have helped shape Atreca since our founding. We greatly
appreciate Larry’s contributions to the company to date and are
grateful that he will continue to support Atreca as both an advisor
and as chairman of our external scientific advisory board.”
Dr. Rolfe brings more than 20 years of drug
development experience to Atreca. Currently, Dr. Rolfe is the Chief
Medical Officer and Executive Vice President of Clinical and
Preclinical Development and Pharmacovigilance at Clovis Oncology,
Inc. Prior to joining Clovis, Dr. Rolfe served in senior oncology
product development roles at Celgene Corporation, Pharmion
Corporation, Cambridge Antibody Technology, UCB Inc. and Celltech
Group plc. Dr. Rolfe received her degree in medicine from the
University of Edinburgh and obtained her post-graduate internal
medicine qualification as a Member of the Royal College of
Physicians (MRCP). She has specialist accreditation in
Pharmaceutical Medicine from the UK General Medical Council and is
a Fellow of the Faculty of Pharmaceutical Medicine.
“I am very excited to join Atreca’s Board during
such an important phase for the company with ATRC-101 advancing
into the clinic early next year,” said Dr. Rolfe. “I believe that
Atreca has a novel and promising approach to drug discovery, which
the company is using to build a pipeline of differentiated product
candidates with the potential to address serious unmet medical need
in solid tumor cancers, and I look forward to working with the team
to bring those therapies to patients.”
About Atreca, Inc.
Atreca is a biopharmaceutical company utilizing its
differentiated platform to discover and develop novel
antibody-based immunotherapeutics to treat a range of solid tumor
types. Atreca’s discovery platform relies on the human immune
system to discover unique antibody-target pairs from patients
experiencing an active immune response against their tumors. These
unique antibody-target pairs represent a potentially novel and
previously unexplored landscape of immuno-oncology targets and
provide the basis for novel clinical therapeutic candidates such as
ATRC-101, the company’s lead clinical candidate. The company
expects to file an Investigational New Drug application for
ATRC-101 by the end of 2019 and to commence a Phase 1b study in
multiple solid tumor types in early 2020. For more information on
Atreca, please visit www.atreca.com.
Forward-Looking Statements This
release contains forward-looking statements regarding our strategy
and future plans, including statements regarding the development of
ATRC-101 and our clinical and regulatory plans, and the timing
thereof. These forward-looking statements include, but are not
limited to, statements about our plans, objectives, representations
and contentions and are not historical facts and typically are
identified by use of terms such as “will”, “expect,” “believe,”
“potential,” “continue,” and similar words, although some
forward-looking statements are expressed differently. Our actual
results may differ materially from those indicated in these
forward-looking statements due to risks and uncertainties related
to the initiation, timing, progress and results of our research and
development programs, preclinical studies, any clinical trials and
Investigational New Drug application and other regulatory
submissions, and other matters that are described in our
prospectus, dated June 19, 2019, as filed with the Securities and
Exchange Commission (SEC) pursuant to Rule 424(b) under the
Securities Act of 1933, as amended, and in our Quarterly Report on
Form 10-Q for the quarter ended June 30, 2019, which are available
on the SEC’s website at www.sec.gov, including the risk factors set
forth therein. Investors are cautioned not to place undue reliance
on these forward-looking statements, which speak only as of the
date of this release, and we undertake no obligation to update any
forward-looking statement in this press release, except as required
by law.
ContactsAtreca, Inc. Herb Cross
Chief Financial Officer info@atreca.com or Media: Burns McClellan,
Inc. Robert Flamm, Ph.D. / Ryo Imai212-213-0006 ext. 364 /
315rflamm@burnsmc.com / rimai@burnsmc.com or Investors: Alex Gray,
650-779-9251, ext. 251 agray@atreca.com
Source: Atreca, Inc.
Atreca (NASDAQ:BCEL)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Atreca (NASDAQ:BCEL)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024